These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 15812200

  • 1. The role of ximelagatran in the treatment of venous thromboembolism.
    Schulman S.
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():18-24. PubMed ID: 15812200
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H, Lundström T, Wåhlander K, Clason SB, Schulman S, THRIVE III Investigators.
    Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
    Harenberg J, Ingrid J, Tivadar F.
    Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H, THRIVE III Investigators.
    N Engl J Med; 2003 Oct 30; 349(18):1713-21. PubMed ID: 14585939
    [Abstract] [Full Text] [Related]

  • 10. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
    Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundström T, Berkowitz SD, Nyström P, Thorsén M, Ginsberg JS, THRIVE Treatment Study Investigators.
    JAMA; 2005 Feb 09; 293(6):681-9. PubMed ID: 15701909
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Ximelagatran for treatment of venous thromboembolism].
    Harenberg J, Fenyvesi T, Jörg I.
    Hamostaseologie; 2002 Aug 09; 22(3):25-9. PubMed ID: 12215758
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.
    Wåhlander K, Eriksson H, Lundström T, Billing Clason S, Wall U, Nyström P, Wessman P, Schulman S, THRIVE III Investigators.
    Br J Haematol; 2006 Apr 09; 133(1):68-77. PubMed ID: 16512831
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [New treatments for venous thromboembolic disease].
    Combe S, Büller HR.
    J Mal Vasc; 2011 Dec 09; 36 Suppl 1():S16-9. PubMed ID: 22177764
    [Abstract] [Full Text] [Related]

  • 20. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug 09; 14(78):127-32. PubMed ID: 16106594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.